Garcia‐Soto et al.35used OY‐TES‐1 recombinant protein to detect its antibody and found that 10% of patients with ovarian cancer had OY‐TES‐1‐specific antibodies in their peripheral blood. Here, DLX2 is linked to ovarian carcinoma.